Home » Newsletters » BioWorld Science

BioWorld Science

July 7, 2003

View Archived Issues

Treatment begins in INGN-225 phase I/II study

rhIGF-I/rhIGFBP-3 enters phase III trial for GHIS

Two series of PDF inhibitors claimed by De Novo scientists

Actelion presents new urotensin-II antagonists for hypertension, atherosclerosis, angina, etc.

Schering researchers prepare and test novel MCH antagonists

New adenosine A1 and/or A3 receptor antagonists under study at OSI

Korean researchers identify novel sPLA2 inhibitors

New Src/MEK kinase inhibitors in early development at AstraZeneca

New trials advance CeNeS pain programs

Connetics submits NDA for Extina in seborrheic dermatitis

Pivotal trial assesses Focalin LA in adults with ADD/ADHD

CA4P evaluated for potential in wet AMD

SAHA enters phase I trial in advanced leukemias

Neurochem clinical advisory board recommends initiation of phase III for Alzhemed

NS-2359 phase I program for ADHD successfully completed

Emtriva approved by FDA for treatment of HIV

Phase I trial initiated for MLN-944

Approval sought for Plenaxis in Germany

British Biotech reviews past year's operations

Fungal metabolites acting on the fungal cell wall discovered by Schering-Plough

Age-related cognitive decline reversed by Eukarion SOD/catalase mimetics

Aricept deemed not approvable for vascular dementia

Water-soluble prodrug of maxi-K channel opener as potential poststroke therapy

APT-070 now holds orphan drug status in transplantation on two continents

Minimal VEGF exon 6-encoded sequence with antiangiogenic activity identified

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 27, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Sumitomo’s DSP-3456 exerts antidepressant-like effects
BioWorld Science
About one-third of patients with major depressive disorder (MDD) are treatment resistant. Ketamine is very effective in treatment-resistant depression, but it is...